Top Page
Prescient Therapeutics Limited
(Sydney:PTX)
Prescient Therapeutics Limited (PTX) vs. iShares MSCI Australia ETF (EWA)
Prescient Therapeutics Limited Business Overview & Revenue Model
Prescient Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.36M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| Gross Profit | 4.36M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| EBITDA | -7.53M | -7.54M | -7.19M | -7.46M | -6.86M | -5.32M |
| Net Income | -7.32M | -7.32M | -8.24M | -7.00M | -5.12M | -4.15M |
Balance Sheet | ||||||
| Total Assets | 14.56M | 14.56M | 20.39M | 28.11M | 17.62M | 20.97M |
| Cash, Cash Equivalents and Short-Term Investments | 6.93M | 6.93M | 14.51M | 21.92M | 12.28M | 16.12M |
| Total Debt | 0.00 | 0.00 | 330.49K | 0.00 | 0.00 | 165.83K |
| Total Liabilities | 3.17M | 3.17M | 2.33M | 2.03M | 856.01K | 539.68K |
| Stockholders Equity | 11.39M | 11.39M | 18.07M | 26.08M | 16.76M | 20.43M |
Cash Flow | ||||||
| Free Cash Flow | -7.24M | -7.24M | -7.40M | -6.19M | -4.32M | -3.97M |
| Operating Cash Flow | -7.24M | -7.24M | -7.40M | -6.19M | -4.31M | -3.97M |
| Investing Cash Flow | 4.00M | 4.00M | 12.00M | -16.00M | -4.43K | -2.31K |
| Financing Cash Flow | -660.97K | -330.49K | 18.15K | 15.83M | 428.29K | 12.75M |
Prescient Therapeutics Limited Technical Analysis
Prescient Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$87.86M | -8.30 | -138.54% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$142.77M | -15.21 | -41.51% | ― | -40.74% | -21.21% | |
50 Neutral | AU$92.53M | -9.67 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$34.90M | -9.09 | -143.71% | ― | 306.88% | ― | |
44 Neutral | AU$108.11M | -12.79 | -47.98% | ― | 700.00% | 26.88% |
Prescient Therapeutics Limited Corporate Events
Prescient Therapeutics Limited has issued 21.78 million unquoted options under its employee incentive scheme, exercisable at A$0.10 and expiring on 17 November 2029. The move is designed to align staff incentives with long-term shareholder value and supports the company’s efforts to retain and motivate key employees as it advances its oncology drug development pipeline.
Prescient Therapeutics Limited has received authorization from the European Clinical Trials Information System to commence a Phase 2a clinical trial of PTX-100 in Italy for patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL). This milestone allows the company to activate trial sites and begin patient recruitment, marking a significant step towards providing a new treatment option for CTCL, a disease with high unmet medical needs.
Prescient Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Gavin Shepherd. The change involves the acquisition of 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting. Such changes in director interests can influence stakeholder perceptions and reflect strategic decisions aligned with the company’s growth and operational objectives.
Prescient Therapeutics Limited announced a change in the director’s interest, with Ellen Gwen Feigal acquiring 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting, reflecting a strategic move to align the interests of the director with the company’s long-term goals, potentially impacting its governance and stakeholder confidence.
Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 2,628,787 unlisted options exercisable at $0.10 each, expiring on November 17, 2029. This acquisition was approved by shareholders at the company’s Annual General Meeting, indicating a strategic move to align the director’s interests with the company’s long-term growth and shareholder value.
Prescient Therapeutics Limited announced a change in the director’s interest, with Allen James Ebens Jr. acquiring 2,628,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting, indicating a strategic move to align the interests of the director with the company’s long-term goals.
Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 5,257,573 unlisted options exercisable at $0.10, expiring on 17 November 2029. This change was approved by shareholders at the company’s Annual General Meeting, indicating strategic alignment and potential growth opportunities for the company.
Prescient Therapeutics Limited has secured Orphan Drug Designation from the European Medicines Agency for PTX-100, a therapy for cutaneous T-cell lymphoma (CTCL), which provides significant benefits such as 10 years of market exclusivity in the EU upon approval. This designation underscores the urgent need for new CTCL treatments and validates PTX-100’s potential to benefit patients across Europe, enhancing Prescient’s commercial pathway in key markets.
Prescient Therapeutics Limited announced the issuance of 12,942,721 unquoted equity securities in the form of options expiring on November 17, 2029, with an exercise price of $0.10. This move is part of an employee incentive scheme and is not intended for quotation on the ASX, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational capabilities and market position.
Prescient Therapeutics announced an amendment to its Constitution following shareholder approval at its Annual General Meeting. This move reflects the company’s ongoing efforts to align its governance with strategic goals as it advances its clinical-stage cancer therapies. The amendment is expected to support Prescient’s focus on developing innovative cancer treatments, potentially impacting its market positioning and stakeholder interests.
Prescient Therapeutics has achieved significant clinical and regulatory milestones, notably advancing PTX-100 to Phase 2a trials and receiving Orphan Drug and Fast Track Designations from the FDA. These developments, alongside a strengthened financial position and leadership team, position the company for accelerated growth and potential market opportunities in the oncology sector.
Prescient Therapeutics Limited has successfully completed a $9.8 million capital raise, bolstering its cash reserves to $12.32 million as of September 2025. The funds will support the ongoing Phase 2 clinical trial of PTX-100, with promising data from a sub-analysis of a Phase 1b trial showing a 43% overall response rate in patients with relapsed and refractory Cutaneous T Cell Lymphoma. The company is expanding its clinical trial sites in Australia, the United States, and potentially Europe, with an orphan drug designation application submitted to the European Medicines Agency. These developments are expected to enhance Prescient’s industry positioning and provide potential market exclusivity in the European Union.